Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1327802rdf:typepubmed:Citationlld:pubmed
pubmed-article:1327802lifeskim:mentionsumls-concept:C0014644lld:lifeskim
pubmed-article:1327802lifeskim:mentionsumls-concept:C0019682lld:lifeskim
pubmed-article:1327802lifeskim:mentionsumls-concept:C0007634lld:lifeskim
pubmed-article:1327802lifeskim:mentionsumls-concept:C0031809lld:lifeskim
pubmed-article:1327802lifeskim:mentionsumls-concept:C0596901lld:lifeskim
pubmed-article:1327802lifeskim:mentionsumls-concept:C0019721lld:lifeskim
pubmed-article:1327802lifeskim:mentionsumls-concept:C0024518lld:lifeskim
pubmed-article:1327802lifeskim:mentionsumls-concept:C0030956lld:lifeskim
pubmed-article:1327802lifeskim:mentionsumls-concept:C1704675lld:lifeskim
pubmed-article:1327802lifeskim:mentionsumls-concept:C0456387lld:lifeskim
pubmed-article:1327802lifeskim:mentionsumls-concept:C0702240lld:lifeskim
pubmed-article:1327802pubmed:issue10lld:pubmed
pubmed-article:1327802pubmed:dateCreated1992-11-10lld:pubmed
pubmed-article:1327802pubmed:abstractTextEarlier findings indicate that peptides can affect the expression of major histocompatibility complex (MHC) class I molecules on the surface of cells with defective peptide loading mechanism. We have used peptide induced increase of class I antigen expression to assess peptide interaction with MHC class I molecules. A panel of 41 overlapping synthetic peptides derived from the human immunodeficiency virus-1 (HIV-1) gag protein and 33 nonoverlapping peptides from Epstein-Barr virus (EBV) proteins EBNA-1, 2, 3, 4, 5, 6, LMP, BZLF2, BILF2, BSLF2, BALF4 and BcLF1 was assessed for the ability to enhance the expression of HLA-A2.1, H-2Db, Kb and Dd on the murine RMA-S and human 721.174/T2 (.174/T2) lines by indirect immunofluorescence. Considering doubling of the fluorescence intensity in the peptide-treated samples as positivity, 6 of 39 HIV and 1 of 32 EBV peptides were found to bind to A2.1, 6 of 39 HIV gag and 7 of 16 EBV peptides to Db, 8 of 39 HIV gag and 5 of 16 EBV peptides to Kb and 2 of 39 HIV gag and 1 of 17 EBV peptides to Dd. The sensitivity of the method is comparable to the in vitro class I assembly assay with conformation-dependent monoclonal antibody and is more discriminating than the solid-phase assay. Due to its simplicity this method can also serve for testing large peptide panels for binding capacity to various class I molecules. Moreover, the method provides information about the relevance of in vitro tests for class I assembly in living cells.lld:pubmed
pubmed-article:1327802pubmed:languageenglld:pubmed
pubmed-article:1327802pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1327802pubmed:citationSubsetIMlld:pubmed
pubmed-article:1327802pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1327802pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1327802pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1327802pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1327802pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1327802pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1327802pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1327802pubmed:statusMEDLINElld:pubmed
pubmed-article:1327802pubmed:monthOctlld:pubmed
pubmed-article:1327802pubmed:issn0014-2980lld:pubmed
pubmed-article:1327802pubmed:authorpubmed-author:KleinGGlld:pubmed
pubmed-article:1327802pubmed:authorpubmed-author:WolfHHlld:pubmed
pubmed-article:1327802pubmed:authorpubmed-author:KärreKKlld:pubmed
pubmed-article:1327802pubmed:authorpubmed-author:ElvinJJlld:pubmed
pubmed-article:1327802pubmed:authorpubmed-author:ModrowSSlld:pubmed
pubmed-article:1327802pubmed:authorpubmed-author:HöglundPPlld:pubmed
pubmed-article:1327802pubmed:authorpubmed-author:StuberGGlld:pubmed
pubmed-article:1327802pubmed:authorpubmed-author:FrankssonLLlld:pubmed
pubmed-article:1327802pubmed:issnTypePrintlld:pubmed
pubmed-article:1327802pubmed:volume22lld:pubmed
pubmed-article:1327802pubmed:ownerNLMlld:pubmed
pubmed-article:1327802pubmed:authorsCompleteYlld:pubmed
pubmed-article:1327802pubmed:pagination2697-703lld:pubmed
pubmed-article:1327802pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1327802pubmed:meshHeadingpubmed-meshheading:1327802-...lld:pubmed
pubmed-article:1327802pubmed:meshHeadingpubmed-meshheading:1327802-...lld:pubmed
pubmed-article:1327802pubmed:meshHeadingpubmed-meshheading:1327802-...lld:pubmed
pubmed-article:1327802pubmed:meshHeadingpubmed-meshheading:1327802-...lld:pubmed
pubmed-article:1327802pubmed:meshHeadingpubmed-meshheading:1327802-...lld:pubmed
pubmed-article:1327802pubmed:meshHeadingpubmed-meshheading:1327802-...lld:pubmed
pubmed-article:1327802pubmed:meshHeadingpubmed-meshheading:1327802-...lld:pubmed
pubmed-article:1327802pubmed:meshHeadingpubmed-meshheading:1327802-...lld:pubmed
pubmed-article:1327802pubmed:meshHeadingpubmed-meshheading:1327802-...lld:pubmed
pubmed-article:1327802pubmed:meshHeadingpubmed-meshheading:1327802-...lld:pubmed
pubmed-article:1327802pubmed:meshHeadingpubmed-meshheading:1327802-...lld:pubmed
pubmed-article:1327802pubmed:meshHeadingpubmed-meshheading:1327802-...lld:pubmed
pubmed-article:1327802pubmed:meshHeadingpubmed-meshheading:1327802-...lld:pubmed
pubmed-article:1327802pubmed:meshHeadingpubmed-meshheading:1327802-...lld:pubmed
pubmed-article:1327802pubmed:meshHeadingpubmed-meshheading:1327802-...lld:pubmed
pubmed-article:1327802pubmed:year1992lld:pubmed
pubmed-article:1327802pubmed:articleTitleAssessment of major histocompatibility complex class I interaction with Epstein-Barr virus and human immunodeficiency virus peptides by elevation of membrane H-2 and HLA in peptide loading-deficient cells.lld:pubmed
pubmed-article:1327802pubmed:affiliationDepartment of Tumor Biology, Karolinska Institute, Stockholm, Sweden.lld:pubmed
pubmed-article:1327802pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1327802pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1327802lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1327802lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1327802lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1327802lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1327802lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1327802lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1327802lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1327802lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1327802lld:pubmed